The burgeoning field of metabolic disease management is witnessing a remarkable convergence of therapies. Tirzepatide , a dual GIP/GLP-1 receptor agonist , alongside Retatrutide , a triple GIP/GLP-1/GCG receptor https://networkbookmarks.com/story21655308/retatrutide-and-nicotinamide-adenine-dinucleotide-a-triple-threat-strategy-to-metabolic-wellness